Thymosin Alpha-1 has a 50-year published research history from its thymic isolation to approval in 35 countries — making it one of the most extensively studied immune-regulatory peptides in clinical and pre-clinical research. This page covers the TLR signalling mechanism, the dendritic cell and T-cell biology, the clinical approval evidence base, and research protocols for immunology studies.
Thymus Biology and the Origin of Thymosin Alpha-1
The thymus gland is the primary site of T-cell development — immature T-cell precursors migrate from bone marrow to the thymus, where they mature into functional T-cells capable of antigen recognition and adaptive immune responses. The thymus produces a family of peptide hormones — collectively called thymosins — that regulate this maturation process. Thymosin Alpha-1 was identified as one of the most biologically active thymic factors, responsible for promoting the final stages of T-cell maturation and enhancing immune competence.
The thymus atrophies progressively after puberty — a process associated with declining T-cell diversity and the age-related reduction in adaptive immune capacity. Thymosin Alpha-1 research was initially motivated by the hypothesis that restoring thymic peptide signalling in aged or immunocompromised individuals might restore T-cell function — a hypothesis that has been partially supported by clinical data in HIV, hepatitis, and cancer patient populations.
Mechanism: TLR Signalling and Dendritic Cell Activation
Clinical Evidence Base
| Indication | Key trial evidence | Outcome | Approval status |
|---|---|---|---|
| Chronic hepatitis B | Multiple RCTs: Tα1 + IFN-α vs IFN-α alone | Higher HBsAg seroconversion rate; HBV DNA reduction | Approved in China, Italy, SE Asia |
| Chronic hepatitis C | Tα1 + IFN-α + ribavirin vs standard of care | Improved sustained virological response (SVR) rate | Approved in some countries as adjunct |
| HIV immunodeficiency | Phase 2 trials in ARC/AIDS patients | CD4+ T-cell count increase vs placebo | Not approved — precedes modern ART era |
| Cancer immunotherapy | Adjunct to chemotherapy — multiple studies | Reduced infections; improved immune reconstitution post-chemo | Approved as adjunct in some markets |
| COVID-19 (2020–2021) | Investigational use in severe cases in China | Proposed benefit in cytokine storm modulation | Emergency use — results mixed |
Research Protocol Reference
| Model | Dose range | Route | Duration | Key endpoints |
|---|---|---|---|---|
| Murine viral infection model | 50–200 μg/kg daily | SC injection | 7–14 days | Viral load, type I IFN levels, NK activity, CTL response, survival |
| Immunosuppressed rodent (cyclophosphamide) | 100–500 μg/kg | SC injection | 14–21 days | T-cell subset recovery (CD4/CD8), NK function, thymic histology |
| Aged rodent immune function | 100–500 μg/kg | SC injection | 4–8 weeks | T-cell diversity, thymic weight, naive T-cell output, vaccine response |
| PBMC dendritic cell activation | 1–100 nM | Cell culture | 24–72hr | Type I IFN production, IL-12/IL-6/TNF-α, surface maturation markers (CD80/83/86) |
| Cancer model (tumour-bearing rodent) | 50–200 μg/kg | SC injection | Duration of study | Tumour growth, NK/CTL infiltration, immune cell composition |
N-terminal acetylation: essential for Thymosin Alpha-1 activity
The natural form of Thymosin Alpha-1 has an N-terminal acetyl group on the serine residue — this acetylation is required for full biological activity. QSC Thymosin Alpha-1 is synthesised with N-terminal acetylation and MS verification confirms the correct molecular weight including the acetyl group on every batch.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced in the thymus gland, derived from prothymosin alpha. It was first isolated and characterised by Allan Goldstein’s group in the 1970s as a thymic hormone responsible for T-cell maturation and immune competence. Tα1 acts primarily through toll-like receptor (TLR) signalling pathways to activate dendritic cells and enhance adaptive immune responses. A synthetic form (thymalfasin) is approved in multiple countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy.
How does Thymosin Alpha-1 work?
Thymosin Alpha-1 activates innate and adaptive immune responses through multiple mechanisms. The primary pathway involves binding and activation of TLR2 and TLR9 on dendritic cells, plasmacytoid dendritic cells (pDC), and T-cells. TLR9 activation by Tα1 stimulates type I interferon (IFN-α/β) production in pDCs — critical for antiviral immunity. TLR2 activation promotes inflammatory cytokine production (IL-12, TNF-α) that bridges innate to adaptive responses. Downstream, Tα1 promotes T-cell maturation in the thymus, enhances Th1 polarisation, increases cytotoxic T-lymphocyte (CTL) activity, and stimulates NK (natural killer) cell function.
What is Thymosin Alpha-1 approved for?
Thymalfasin (synthetic Thymosin Alpha-1) is approved in approximately 35 countries including Italy, China, and across Southeast Asia as an immune adjuvant. Approved indications include chronic hepatitis B (reducing viral load and promoting seroconversion), chronic hepatitis C (in combination with interferon and ribavirin), and as an adjunct in cancer chemotherapy to reduce immunosuppression. It is not approved by the FDA in the United States, where it remains an investigational research compound.
What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?
Thymosin Alpha-1 and Thymosin Beta-4 (TB-500) are both thymic peptides but with entirely different biology. Thymosin Alpha-1 is immune-regulatory — it promotes T-cell maturation, dendritic cell activation, and type I interferon responses. Thymosin Beta-4 is primarily involved in actin dynamics, cell migration, and tissue repair. They do not share receptor targets or signalling pathways. They are sometimes confused due to similar naming, but are mechanistically unrelated.
What purity does QSC supply for Thymosin Alpha-1?
QSC Thymosin Alpha-1 is a 28-amino acid synthetic peptide verified at ≥99% purity by HPLC and confirmed by mass spectrometry on every batch. The N-terminal acetylation (required for biological activity) is confirmed by MS. Janoshik-independent COA is published on the product page.
Thymosin Alpha-1 · BPC-157 · TB-500